4882
antibody from Cell Signaling Technology, Inc
Targeting: NFKB2
LYT-10, NF-kB2, p105, p49/p100, p52
Antibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 4882 - Provider product page
- Provider
- Cell Signaling Technology, Inc
- Proper citation
- Cell Signaling Technology Cat#4882, RRID:AB_10695537
- Product name
- NF-κB2 p100/p52 Antibody
- Antibody type
- Polyclonal
- Reactivity
- Human, Mouse, Rat, Simian
- Host
- Rabbit
- Storage
- -20°C
Submitted references p100 Deficiency is insufficient for full activation of the alternative NF-κB pathway: TNF cooperates with p52-RelB in target gene transcription.
Tumor-associated a2 vacuolar ATPase acts as a key mediator of cancer-related inflammation by inducing pro-tumorigenic properties in monocytes.
Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation.
Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines.
NF-kappaB modulates aquaporin-2 transcription in renal collecting duct principal cells.
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.
Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.
Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta.
Rescue of TRAF3-null mice by p100 NF-kappa B deficiency.
Lovas A, Weidemann A, Albrecht D, Wiechert L, Weih D, Weih F
PloS one 2012;7(8):e42741
PloS one 2012;7(8):e42741
Tumor-associated a2 vacuolar ATPase acts as a key mediator of cancer-related inflammation by inducing pro-tumorigenic properties in monocytes.
Kwong C, Gilman-Sachs A, Beaman K
Journal of immunology (Baltimore, Md. : 1950) 2011 Feb 1;186(3):1781-9
Journal of immunology (Baltimore, Md. : 1950) 2011 Feb 1;186(3):1781-9
Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation.
Razani B, Zarnegar B, Ytterberg AJ, Shiba T, Dempsey PW, Ware CF, Loo JA, Cheng G
Science signaling 2010 May 25;3(123):ra41
Science signaling 2010 May 25;3(123):ra41
Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines.
Lu YC, Kim I, Lye E, Shen F, Suzuki N, Suzuki S, Gerondakis S, Akira S, Gaffen SL, Yeh WC, Ohashi PS
Journal of immunology (Baltimore, Md. : 1950) 2009 Jun 1;182(11):7212-21
Journal of immunology (Baltimore, Md. : 1950) 2009 Jun 1;182(11):7212-21
NF-kappaB modulates aquaporin-2 transcription in renal collecting duct principal cells.
Hasler U, Leroy V, Jeon US, Bouley R, Dimitrov M, Kim JA, Brown D, Kwon HM, Martin PY, Féraille E
The Journal of biological chemistry 2008 Oct 17;283(42):28095-105
The Journal of biological chemistry 2008 Oct 17;283(42):28095-105
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.
Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M, Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J
The Journal of cell biology 2008 Jul 14;182(1):171-84
The Journal of cell biology 2008 Jul 14;182(1):171-84
Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.
Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, Shiba T, Yang X, Yeh WC, Mak TW, Korneluk RG, Cheng G
Nature immunology 2008 Dec;9(12):1371-8
Nature immunology 2008 Dec;9(12):1371-8
Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta.
Solt LA, Madge LA, Orange JS, May MJ
The Journal of biological chemistry 2007 Mar 23;282(12):8724-33
The Journal of biological chemistry 2007 Mar 23;282(12):8724-33
Rescue of TRAF3-null mice by p100 NF-kappa B deficiency.
He JQ, Zarnegar B, Oganesyan G, Saha SK, Yamazaki S, Doyle SE, Dempsey PW, Cheng G
The Journal of experimental medicine 2006 Oct 30;203(11):2413-8
The Journal of experimental medicine 2006 Oct 30;203(11):2413-8
No comments: Submit comment
No validations: Submit validation data